Background: Chemotherapy of non-small-cell lung cancer (NSCLC) has been improved by the use of cis-platin (P) and the pyrimidine antimetabolite gemcitabine (G) (29,29-difluorodeoxycytidine). GP regimens currently used in Italy for NSCLC were and are mainly based on G day 1, 8 and 15; P on day 2, every 28 days (4 Day-Hospital admissions per cycle). However, the third G dose is frequently omitted because of myelo-toxicity, with a consistent dose decrease of both G and P in comparison with the intended dose. The 24-h lag time from 1 st G and P has not reasonable clinical pharmacology base.
introduction
The chemotherapy of advanced NSCLC, stages IIIB or IV, has been improved by the use of cis-platin (P), as eventually confirmed by us [1] and by the BMJ metanalysis [2] .
Gemcitabine (29-29-difluorodeoxycytidine) (G) has been considered among the best candidates for combination with P and several studies have confirmed the effectiveness of the combination [3] [4] [5] [6] [7] [8] [9] . Most used GP combinations, at least in Italy, are based, or planned to be, on G administered on day one, eight and fifteen. P is given on day two and the combination is recycled every twenty-eight days [5, 9] . There is not a clear demonstration that administering P, 24 h after the first G, has a clinical pharmacology base. Each cycle of this combination regimen is based on four day-hospital admissions. The previewed G dose intensity could not be consistently maintained owing to the omitted fifteenth day-dose because of myelotoxicity, i.e. grade 3-4 neuthropoenia and thrombocytopenia in a 36% and 52% of patients respectively [9] . In the initial phase II, as the RR and median survival are concerned, figures were 54% and 14 months, respectively [5] . In the subsequent phase III, the same authors with the same GP combination in stage IV patients obtained a RR of 38% and the median survival was 8.6 months [9] . These last two figures were not statistically superior to those obtained in the control MIC (mitomycin, ifosfamide and P) arm, but the GP regimen was less toxic [9] . The 8.6 months median survival obtained with such a combination was closed also to that observed in our phase III study including only stage IV disease and based on P, M and Cyclophosphamide (PMC) regimen (8.5 months) [1] .
We devised a simplified GP regimen based on only two hospital admissions every 3 weeks, with P immediately following symposium article G on day eight, and a pilot study was reported [10] . Besides the analysis of toxicity and Quality of Life (QoL), aim of the study was the RR as obtainable over a short number of cycles, i.e. three, to possibly propose the GP regimen in the neoadjuvant therapy setting. Secondly, we evaluated the patients' survival. In 95 patients evaluable after at least three cycles, the RR was 57.9%. Additional three therapy cycles did not add any RR improvement and the median overall survival was seventeen months. In the 105 patients population the intention to treat analysis gave a 16 months median overall survival (MOS), and in the 95 valuable patients the MOS was 17 months.
patients and methods
The investigation was designed as a controlled, prospective, multi-centre, nonrandomized study, and was performed on consecutive patients. /l, creatinine clearance £65 mg/min with 24-hour urine collection, and serum bilirubin level £35 lmol/l. Exclusion criteria included uncontrolled hypertension or angina pectoris, acute myocardial infarction or central nervous system stroke within the previous 3 months, arterial Buerger disease, and a second primary tumor other than non melanoma cutaneous cancer.
In addition to physical examination, the disease staging included bronchoscopy possibly with direct or transbronchial biopsy; total body 99 mTc total body bone scan; and abdominal, pelvic, and brain computed tomography. When necessary for diagnosis, lung or liver biopsy was performed; when bone scan indicated suspicious disease, X-ray tomography plus/minus CT of bone segment were performed.
Forty-six patients (three patients with unresactable IIIA, six with IIIB and thirty-seven with stage IV), as personally followed by the senior investigator (G.C.), were evaluated for EORTC C30-LC13 quality of life.
Informed consent was obtained, according to contemporaneous Italian regulations and the study was performed on the approval by the FVG (Friuli Venezia Giulia) institutional review board.
supportive care
Supportive care [1] consisted of analgesics, an antitussive, relief of increased intracranial pressure, palliative radiotherapy, and treatment of infections and pleural effusion. For analgesia, patients were medicated on a regular cyclic schedule, instead of an 'as needed' basis. Treatment included the following: dicoflenac sodium (50-100 mg) every 24 h, to be escalated up to every 18 or 12 or 6 h, with or without lorazepam (1 mg up to 2.5 mg, every 24 h), if required. When the 24 h dose of dicoflenac sodium reached 150 mg, 20 mg omeprazole was added at 8:00 a.m. Further steps in analgesia were cyclic daily doses of oral morphine sulphate (from 10 mg), or buprenorphine hydrochloride (0.3 mg intramuscular injection or 0.2 mg sublingual tablet). Neuronal anesthesia by means of an epidural catheter was available if clinically required. Methylprednisolone (40-125 mg/day, given intravenously) was used for analgesia at 9:00 a.m., also given by the epidural route (40 mg) if required. To relieve increased intracranial pressure, i.m. dexamethasone was given (8 to 12 mg/day), together with i.v. mannitol. Therapy for pleural effusion include fluid drainage and local instillation of P (25 to 50 mg). Oral codeine salts were the antitussive of choice. For infections, the first antibiotic was oral ciprofloxacin 500 to 750 mg/day. When required, palliative radiotherapy was given for painful osseous metastasis or impeding bone fractures, for brain metastases that developed after enrollment, or for superior vena cava obstruction. treatment schedule G (1500 mg/m 2 ) on day 1 and 8, and P (100 mg/m 2 ) on day 8 following G, were administered on a 3-week cycle. The rationale of giving G first and P second, has already been proposed and discussed by us [10] . We devised the regimen, having in mind a therapy-cycle based on two administrations of drug since after administration of the first G-dose a relevant myelo-toxicity is unlikely, thus, the second the administration of G plus P could be delivered on day 8, with a good dose intensity saving, allowing the onset of leucopenia and thrombocytopenia after day eight. P was placed on day 8 instead of 2 because of the theoretical rationale mentioned above [11] , and also because of a smaller risk of the myelo-toxicity which could have hastened the day 8 chemotherapy [12] . assessment Adverse events, vital signs, and laboratory measurements (full blood count, blood creatinine, total and conjugated bilirubin, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), alkaline phosphatases, and routine chemistry) were monitored to evaluate the safety and tolerability of the regimen. Full blood count and serum creatinine were mandatory before each cycle. Performance status and body weight (kg) were recorded every 3 weeks. Basally and every 3 cycles a complete assessment included personal history, physical examination, chemistry as above, chest and abdominal computed tomography scans. Brain CT scan was made basally and subsequently only in patients with central neurological symptoms. All the radiological measurements that demonstrated an improvement (i.e. reduction of the disease) were collegially reviewed.
A complete response was defined as the complete disappearance of all clinically detectable malignant disease for > 4 weeks with no appearance of new disease. A patient who had radiographic evidence of bony metastases prior to therapy had to have normalization of radiographs or sclerotic healing of lytic metastases in association with a normalized bone scan. A PR was defined as more than 50% decrease from baseline in the product of the areas of all measurable lesions for > 4 weeks with no appearance of new disease. Stable disease was defined as no significant change in measurable or valuable disease for more than a month and no significant chance in bony metastases for 12 weeks. A < 50% decrease or a £ 25% increase in metastases at any sites and no deterioration in Karnofsky performance status of greater than or equal to 10 points was also defined as stable disease. Progression of disease was defined as a more than 25% increase in any lesion, reappearance of measurable disease, appearance of any new lesions (including brain metastases even if there was response outside of the brain), or significant worsening condition presumed to be related to malignancy (i.e. a decline in performance status).
results
Patients' characteristics are shown in Table 1 . The GP regimen was tolerated and myelo-toxicity was acceptably low (Table 2) . Ten patients were invaluable for toxicity and response because of (a) 2 patients never received therapy because of refusal after enrollment into the study (with IIIA and IIIB disease, respectively); (b) death due to lung thrombo-embolism (patient with stage IIIA disease)), fast progression of the disease (patient with stage IV disease); (c) five patients having received less than three cycles at the present analysis (1, 1, 1, and 2 cycles per patient, respectively, with, in the same order, stage IV, IIIB, IIIB, IIIA and IV disease). Therapy cycles were 488 (from one to six per patient). Ninety-five patients received 285e t.c. (3 per patient), and 66 of them received further three therapy cycles each, i.e. 198 (totaling 483).
In the 95 valuable patients over the first 42 days, i.e. after 2 cycles and just before the third cycle, 10 out of 190 were delayed by 1 week because of myelotoxicity. During this period, GCSF was given once a week. The dose intensity of both the drugs was reduced by 5.29%.
In the ninety-five patients, after three cycles of therapy, results were: 55 PR (57.9%) and 26 stable disease (SD) (27.3%) (see also Table 3 ). In these 95 patients the median overall survival was seventeen months; after twenty-four months 24.2%, and 10.5% after thirty months; no patient was alive at 49th month (see Table 5 ). In the entire group of 105 patients the intention to treat analysis showed a median overall survival of 16 months.
In Table 4 results of QoL analysis are given. It should be worthwhile to observe that a significant (P < 0.05) improvement of QoL (functional scale) occurred both at physical and emotional levels, in comparison with basal conditions. The global QoL scale ameliorated (81 vs. 60 score), however without reaching a significant (P) figure. With regard to the symptoms scale, fatigue and insomnia decreased (p not significant), and pain was statistically reduced (P < 0.05). Alopecia was consistently caused by the therapy. Even if the observed patients were 46 (48.4%), the effect of three chemotherapy cycles was consistently good.
discussion
Present results confirm that the association of P and G may be considered a suitable regimen for NSCLC. Our GP pilot study on previous patients [10] has been confirmed. In comparison with previous phase II studies some differences could be underwritten. The number of evaluable consecutive patients (see Table 1 ) was 95, greater than in previous studies [5] [6] [7] [8] [9] . Besides that, two other considerations arise. Despite we have reduced the day-hospital admissions from 4 to 2 per cycle, with evident less patients' discomfort and financial expenses (especially the aged patients must come to the hospital accompanied by someone), the response rate and the median survival was appreciably good or even better than in previous studies[1 -9] . These last results may be related to a greater respect of the intended dose intensity of both G and P that was here obtained by postponing P to the 8 th day of the cycle. The two G doses and the one P dose per cycle every 21 days allowed us to obtain a greater dose intensity than the three G doses and the one P dose per cycle every 28 days [9] , i.e. a 4-week regimen in that the third G dose having been omitted in a relevant percentage of patients. The intended dose intensity of P (100 mg/m 2 every 21 days) in our regimen in comparison with Other's regimen [5] [6] [7] [8] [9] every 28 days, resulted in 33 mg/week instead of 25 mg/week, that is 14% in favour of our regimen. After three cycles results were: 55 PR (57.9%) and 26 stable disease (SD) (27.3%) (see Table 3 ). The median overall survival was seventeen months. Survival after eighteen months was 45.3%, 24.2% after twentyfour months, 10.5% after thirty months. No patient was alive after forty-nine months (see Table 5 ). In the entire group of 105 patients the intention to treat analysis showed a median overall survival of 16 months, with 52% PR and 24.8% SD.
The percentage of patients who had a myelo-toxicity or any other toxicity capable of delaying the previewed administration of the 8 th -day drugs over the first three cycles was truly minimal (9 delayed cycles out of 190). Complete remission plus SD are in the middle way from the above quoted phase III study results in 48 patients [5] and the results with G, P and Ifosfamide in 8 patients [14] .
We have to remember that among our enrolled patients in progression after radiation, and considered unsuitable to surgery, only 13 (13.7%) had a stage IIIA disease. This group of patients had not better results than patients with IIIB and IV stage disease. Tolerance was good, toxicity amenable, and results were encouraging.
From present results, and those by Santo et al. [15] who used the same drug scheduling regimen, we may say that the rationale of giving G first and P second is correct. And especially P immediately following the 8 th -day G-dose could have been more synergistic than that given 24 h later (day 1 G; day 2 P). This question cannot be surely answered because present research was based nor on pharmacokinetic studies, neither on direct comparison of the two different therapy schedules. The PNS toxicity was long standing and frequently worst (up to G 3) within the immediate two months next the sixth therapy cycle. In 79 patients who completed such a length of therapy the quoted PNS toxicity grade 3 take some 2 to 6 months (medially 3½) to reduce to grade 2, and eventually to grade 1 over the following 6 months.
Among present patients, a group of 36 (36.8%) has been personally followed by the senior author (G. C.) for the QoL evaluation. No worsening caused by chemotherapy occurred in the evaluated patients; and the global QoL scale ameliorated (81 vs 60 score), however without reaching a significant (P) figure. Survival was not the first aim of present phase II study. However, owing to the appreciable great number of treated patients, the survival behaviour was calculated ( Table 5 ). The median overall survival was 17 months; 24.2% of patients being alive at 2 years; 10.5% at 30 months, no patients survived above 49 months. The Authors of the initial GP [9] , by considering the reduction of G dose (median dose 706 mg/m 2 ) and of P (median dose 86 instead of the planned 100 mg/m 2 ) subsequently suggested a 21-day schedule with P 70 mg/m 2 (day 1 and 8), and this regimen gave a comparable results with the more complex one [16] . A Spanish group used G 1250 mg/m 2 day 1 again obtaining comparable results [17] .
The relative high RR we obtained in 95 consecutive patients with the first three full dose GP cycles encourage this therapy in the neoadjuvant setting. In the search of an intensive either presurgery or pre-radiation chemotherapy over a short time, the previewed dose density and intensity should be maintained. Thus, the use of few GCSF doses over this neoadjuvant induction therapy may be regarded as a simple, tolerable and safe procedure. As stated before, GCSF was used as a precaution in patients living far from hospitals. Delay or dose-reduction during the first 42 days of therapy (the 3 cycles were given on day 1, 21 and 42) was relatively minimal; out of 190 cycles only 9 cycles were delayed by 1 week, just before the 3 rd cycle. In conclusion we can recommend three cycles of present regimen in the neo-adjuvant setting.
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